



**Clinical History:**

Age: \_\_\_\_\_

Race: \_\_\_\_\_

Gender: \_\_\_\_\_

Menopausal Status: \_\_\_\_\_

Risk Factors: \_\_\_\_\_

Osteoporosis Therapy: \_\_\_\_\_

Comparison Study: \_\_\_\_\_

**Technique:** (equipment type) \_\_\_\_\_

**RESULTS**

**PA Lumbar Spine:**

BMD measured in \_\_\_\_\_ region of interest is \_\_\_\_\_ g/cm<sup>2</sup>.

T-score: \_\_\_\_\_ Z score: \_\_\_\_\_

Comments: [None] \_\_\_\_\_

**Proximal Femur:**

BMD measured in \_\_\_\_\_ region of interest is \_\_\_\_\_ g/cm<sup>2</sup>.

T-score: \_\_\_\_\_ Z score: \_\_\_\_\_

Comments: [None] \_\_\_\_\_

**Forearm:**

BMD measured in \_\_\_\_\_ region of interest is \_\_\_\_\_ g/cm<sup>2</sup>.

T-score: \_\_\_\_\_ Z score: \_\_\_\_\_

Comments: [None] \_\_\_\_\_

**CONCLUSIONS:**

- Diagnosis: \_\_\_\_\_
- Fracture Risk: \_\_\_\_\_
- Monitoring: \_\_\_\_\_
- Treatment Recommendations: \_\_\_\_\_
- Follow up DXA: \_\_\_\_\_

**PLEASE NOTE:**

- T-score compares patient BMD to a reference of young normal controls.
- Z-score compares patient BMD to age, gender, and race matched controls.

**World Health Organization Classification:**

Osteoporosis: T-score = -2.5 or below.

Osteopenia (low bone mass): T-score between -1.0 and -2.5.

Normal: T-score -1.0 or above.

**National Osteoporosis Foundation** recommends pharmacologic therapy in postmenopausal women and men > 50 y/o with:

- Hip or vertebral (clinical or morphometric) fractures
- T-score  $\leq$  -2.5 at the femoral neck, total hip, or spine
- T-score between -1 and -2.5 with prior fractures or secondary causes of osteoporosis.
- T-score between -1 and -2.5 with 10 year probability of hip fracture  $\geq$  3%

-or-

10 year probability of any major osteoporosis-related fracture  $\geq$  20%